Revenue grew 7.71% year-over-year to ¥1,593 million, but net loss attributable to shareholders reached ¥24.05 million. Increased R&D and sales expenses reflect a strategic focus on biopharma, highlighted by the acquisition of a larger stake in Jushi Biopharma.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.